Rigel Pharmaceuticals
(NASDAQ) RIGL
Rigel Pharmaceuticals Financials at a Glance
Market Cap
$787.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$299.77M
Net Income (TTM)
$364.23M
EPS (TTM)
$18.72
P/E Ratio
2.27
Dividend
$0.00
Beta (Volatility)
1.36 (Average)
Dividend
$0.00
Beta (Volatility)
1.36 (Average)
Price
$42.49
Volume
462,528.264
Open
$43.76
Price
$42.49
Volume
462,528.264
Open
$43.76
Previous Close
$42.55
Daily Range
$41.57 - $43.99
52-Week Range
$18.65 - $52.24
Estimated Earnings Date
Aug 4, 2026
Dividend
$0.00
Beta (Volatility)
1.36 (Average)
Price
$42.49
Volume
462,528.264
Open
$43.76
Previous Close
$42.55
Daily Range
$41.57 - $43.99
52-Week Range
$18.65 - $52.24
Estimated Earnings Date
Aug 4, 2026
RIGL News
RIGL: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Rigel Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
174
CEO
Raul R. Rodriguez, MBA
Website
www.rigel.comHeadquarters
South San Francisco, CA 94080, US
RIGL Financials
Key Financial Metrics (TTM)
Gross Margin
93.39%
Operating Margin
41.56%
Net Income Margin
121.51%
Return on Equity
147.03%
Return on Capital
28.21%
Return on Assets
72.18%
Earnings Yield
44.05%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$787.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
18.50M
Volume
462.53K
Avg. Volume
398.30K
Financials (TTM)
Gross Profit
$279.95M
Operating Income
$124.58M
EBITDA
$131.28M
Operating Cash Flow
$79.27M
Capital Expenditure
$0.00
Free Cash Flow
$79.27M
Cash & ST Invst.
$146.68M
Total Debt
$45.72M
Rigel Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$58.82M
+10.3%
Gross Profit
$54.21M
+10.8%
Gross Margin
92.17%
N/A
Market Cap
$787.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$4.52M
N/A
Employees
174
N/A
Net Income
$8.65M
-24.4%
EBITDA
$13.69M
-2.0%
Quarterly Fundamentals
Total Cash
$146.68M
+90.3%
Total Debt
$45.72M
-25.1%
Accounts Receivable
$49.95M
+20.2%
Inventory
$11.65M
+150.1%
Long Term Debt
$15.22M
-66.8%
Short Term Debt
$30.50M
+99.7%
Return on Assets
72.18%
N/A
Return on Invested Capital
30.01%
N/A
Free Cash Flow
$2.73M
+405.2%
Operating Cash Flow
$2.73M
+405.2%